Olga O. Voronkova

Dr. Olga O. Voronkova

Sechenov University, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Moskva, Russia
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2019 in Kardiologiia
Verified
Journal Article
Open access
PDF file
YBYu. N. Belenkov
Yu. N. Belenkov
OTO. A. Tsvetkova
O. A. Tsvetkova
EPE. V. Privalova
E. V. Privalova
GAG. V. An
G. V. An
III. S. Ilgisonis
I. S. Ilgisonis
OVOlga O. Voronkova
Olga O. Voronkova
Chronic obstructive pulmonary disease (COPD) is the fourth largest cause of worldwide mortality. Presence of comorbidities is registered in 96% of COPD patients. The most important of these are cardiovascular diseases (coronary artery disease, arterial hypertension, chronic heart failure), which contribute to COPD patients’ mortality in every third case. COPD and cardiovascular diseases have common risk factors and pathogenesis mechanisms. Cardioselective beta-blockers reduce morbidity risk and frequency of COPD exacerbation, are effective and safe in treatment of COPD patients.

4 May 2020 in Kardiologiia
Verified
Journal Article
Closed access
PDF file
OVOlga O. Voronkova
Olga O. Voronkova
OTO. A. Tsvetkova
O. A. Tsvetkova
SASergey Avdeev
Sergey Avdeev
ERE. F. Rogova
E. F. Rogova
GAG. B. Abdullaeva
G. B. Abdullaeva
The article presented a clinical case of 8-year follow-up of a patient with a relatively beneficial course of pulmonary sarcoidosis and intrathoracic lymph nodes and with gradually progressing myocardial injury. A specific feature of the case was that the patient had monoclonal gammopathy, which is extremely rarely reported. Morphological signs of paraproteinemic hemoblastosis and amyloidosis were not observed. The article considered a whole complex of studies, which is required for diagnosing cardiac sarcoidosis in a specific patient and addressed the issue of monoclonal gammopathy origination.

10 February 2023 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
OTO. A. Tsvetkova
O. A. Tsvetkova
OVOlga O. Voronkova
Olga O. Voronkova
OBO. E. Buyanova
O. E. Buyanova
ADA. O. Dubinin
A. O. Dubinin
According to the World Health Organization, chronic obstructive pulmonary disease is the third leading cause of death in 2020, accounting for approximately 6% of all deaths.Aim. We studied how matrix metalloproteinases affect the likelihood and severity of chronic obstructive pulmonary disease.Methods. The study included 60 patients aged 40 to 85 years with chronic obstructive pulmonary disease (7 women and 53 men). The average age of the patients was 63.2 ± 8.3 years. The smoker index ranged from 10 to 118 pack/years. We divided all examined patients into two groups by the severity of the disease, by age, by the duration of the disease, and by the clinical forms.Results. Among the 60 examined patients, we did not identify a single patient with polymorphic variant C536T of TIMP-1 gene. All patients were homozygous and had the CC genotype. We found that only C-1562T polymorphism of MMP-9 gene is associated with severe COPD (p = 0.014), out of all studied variants of MMP-1, MMP-9, and MMP-12 genes. We did not find a reliable relationship between polymorphic variant C-1562T of MMP-9 gene and emphysematous changes in the lungs. We did not find a significant effect of polymorphic variants of MMP-1 and MMP-12 genes on the severity of COPD and the nature of structural changes in the lung tissue. As a result, we can assume that future studies should focus more on the relationship between the dominant pathogen and the level of matrix metalloproteinases. Understanding this relationship will allow us to influence the course and prognosis at an earlier stage of the disease. Our data on the leading role of polymorphism of MMP-1, MMP-9, and MMP-12 genes and other candidate genes are also confirmed by other recently published scientific papers.Conclusion. This study established the presence of genetic markers for a poor prognosis of COPD. Smokers and people subject to occupational hazards are most susceptible to these factors.

24 November 2018 in Kardiologiia
Verified
Journal Article
Open access
PDF file
OTO. A. Tsvetkova
O. A. Tsvetkova
OVOlga O. Voronkova
Olga O. Voronkova
GAG. B. Abdullaeva
G. B. Abdullaeva
Острое лекарственное поражение легких на фоне приема амиодарона

13 April 2023 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
OVOlga O. Voronkova
Olga O. Voronkova
ASA. A. Starzhevskaia
A. A. Starzhevskaia
VSV. G. Skachek
V. G. Skachek
ERE. F. Rogova
E. F. Rogova
GAG. B. Abdullaeva
G. B. Abdullaeva
YBYuri Belenkov
Yuri Belenkov
The subacute period of coronavirus infection is a 4- to-12-week period after acute illness associated with the SARS-CoV-2 infection. A range of bronchopulmonary symptoms in the subacute period of COVID-19 includes cough, shortness of breath, reduced exercise tolerance, which, in turn, worsens the patient’s quality of life. Despite all the achievements of modern medicine, there is still no exact understanding of the mechanisms of this condition. There are also limitations of current patients’ treatments. The successful use of exogenous surfactant in the acute period of SARS-CoV-2 infection has become the starting point in the search for new therapeutic tools for this category of patients. The paper describes a clinical observation with the use of inhaled therapy with surfactant 150 mg/day for 7 days in a patient who underwent COVID-associated pneumonia with persistent ventilation disorders, decreased exercise tolerance, and characteristic changes identified due to the multispiral computed tomography examination. The treatment included the use of the Russian-manufactured surfactant (tauractant), a lyophilisate for suspension for endotracheal, endobronchial and inhalation administration, 75 mg vials. The drug is sourced from bovine lungs, refers to ATC R07AA30 (therapeutic combinations comprising pulmonary surfactants); pharmacotherapeutic group: surfactant. The studied treatment demonstrated the efficacy and safety of administration in this category of patients, and also ensured the disease control and improved quality of life.

22 November 2020 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
ОTО. A. Tsvetkova
О. A. Tsvetkova
OVOlga O. Voronkova
Olga O. Voronkova
The purpose of the article is to determine the place of the combined bronchodilator fenoterol + ipratropium bromide in the treatment of exacerbations of bronchial asthma, COPD and recommendations on various delivery methods. The treatment of exacerbations of bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) is of interest to a general practitioner. Although this concept has lost most of its gloomy colors in the last decade thanks to the new concept of diagnosing and treating patients, the problem of providing qualified timely assistance at the time of an exacerbation remains acute and not always solvable. Often the basis for the treatment of exacerbation of asthma and COPD is repeated administration of a fast-acting inhaled short-acting b2-agonist or an anticholinergic drug, or their combination, early administration of systemic corticosteroids and oxygen inhalation. Exacerbation therapy should be as safe as possible for patients. Following the recommendations for the treatment of asthma and COPD exacerbations both on an outpatient basis and in a hospital can significantly reduce the frequency of asthma and COPD exacerbations. Medical care that a patient can receive at home depends on the experience of the physician and the patient, as well as on the possibilities of medicine and instrumental provision. Ideally, the level of peak expiratory flow (PEF) should be a measure of control over one’s well-being, both in remission and in an exacerbation.